Resolian
Global contract research organization providing bioanalytical, analytical sciences, and supporting laboratory services across preclinical and clinical drug development. Offers method development and validation, DMPK support, ultra-trace impurity analysis, materials characterization, forensic particulate analysis, and sample management via a harmonized multi-site network (US, UK, China, Australia) with GxP-compliant quality systems.
Industries
Nr. of Employees
large (251-1000)
Resolian
Malvern, Pennsylvania, United States, North America
Products
Biomarker assay list (downloadable)
Comprehensive list of available biomarker assays and methods; additional methods can be developed on request.
Scientific posters and methodological resources (downloadable)
Technical posters and case study resources on topics such as nitrosamine testing, green E&L methods, SFC methods and peptide permeability assay optimisation.
Biomarker assay list (downloadable)
Comprehensive list of available biomarker assays and methods; additional methods can be developed on request.
Scientific posters and methodological resources (downloadable)
Technical posters and case study resources on topics such as nitrosamine testing, green E&L methods, SFC methods and peptide permeability assay optimisation.
Services
Comprehensive bioanalysis including PK/PD/TK, immunogenicity, biomarker quantification and method transfer across global sites.
CMC testing, impurity identification, extractables & leachables profiling, elemental analysis and materials characterisation for pharmaceutical products and devices.
In vitro reaction phenotyping, metabolite identification and pharmacokinetic support including CES phenotyping and supersome-based assays.
Rapid forensic workflows to isolate and identify visible and sub-visible contaminants using microscopy, spectroscopy and elemental techniques to determine source and root cause.
Comprehensive bioanalysis including PK/PD/TK, immunogenicity, biomarker quantification and method transfer across global sites.
CMC testing, impurity identification, extractables & leachables profiling, elemental analysis and materials characterisation for pharmaceutical products and devices.
In vitro reaction phenotyping, metabolite identification and pharmacokinetic support including CES phenotyping and supersome-based assays.
Rapid forensic workflows to isolate and identify visible and sub-visible contaminants using microscopy, spectroscopy and elemental techniques to determine source and root cause.
Expertise Areas
- Bioanalytical method development and validation
- Ultra-trace impurity analysis (nitrosamines, NDSRIs)
- Drug metabolism and pharmacokinetics (DMPK)
- Extractables & leachables profiling
Key Technologies
- LC-MS/MS
- High-resolution mass spectrometry (HR-MS)
- Hydrophilic interaction liquid chromatography (HILIC)
- Supercritical fluid chromatography (SFC-UV)
News & Updates
Case profile describing a bursary winner presenting LC-MS/MS stability work; highlights support for early-career development and method development experience.
Report on redeveloping LC-HRMS E&L screening methods using greener solvents and runtime optimization to reduce environmental impact without loss of sensitivity.
Method development article demonstrating HILIC-MS approach for NMBA achieving 0.8 ng/mL quantification in diverse formulations.
Reported analysis of over 5,000 particles in forensic foreign-matter investigations to inform source identification and remediation.
Stated multi-site regulatory inspection success and experience with FDA, EPA, EMA, MHRA and NATA inspections and GxP-compliant systems.
Case profile describing a bursary winner presenting LC-MS/MS stability work; highlights support for early-career development and method development experience.
Report on redeveloping LC-HRMS E&L screening methods using greener solvents and runtime optimization to reduce environmental impact without loss of sensitivity.
Method development article demonstrating HILIC-MS approach for NMBA achieving 0.8 ng/mL quantification in diverse formulations.
Reported analysis of over 5,000 particles in forensic foreign-matter investigations to inform source identification and remediation.
Stated multi-site regulatory inspection success and experience with FDA, EPA, EMA, MHRA and NATA inspections and GxP-compliant systems.